Status: Recruiting
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
Phase 1b/2 Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)
Participants needed: 90
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: 35Pharma IncUpdated: Aug 17, 2026Locations: 2
Eligibility criteria
Male and female participants, 18 years of age and older. [+8]
PH WHO Groups 2, 3, 4 or 5. [+15]